Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02030418 · ClinicalTrials.gov registry record · NA
The LEADLESS II IDE Study for the Nanostim Leadless Pacemaker
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 952
- Enrollment target
NCT02030418: Completed NA study, sponsored by Abbott Medical Devices.
NCT02030418 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 952 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02030418, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 952 participants
- Enrollment target
Study Summary
Prospective, non-randomized, single-arm, international multicenter, clinical safety and effectiveness of a leadless pacemaker system in patients who are indicated for a VVIR pacemaker. Following completion of enrollments in the IDE, patients will continue to be enrolled in the continued access phase of the study under the same protocol.
Primary Outcome
Complication is any device-or-procedure related serious adverse event, or serious adverse device effect, including those that prevented initial implantation. Percentage of participants free from complications are reported
Interventions
- DEVICE Leadless Pacemaker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 952 participants |
| Start Date | 2014-02 |
| Est. Completion | 2022-07-15 |
| Phase | NA |
What the finished NCT02030418 record still lists
NCT02030418 is an interventional study that assigns participants to a tested intervention. The registered 952 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 1 intervention - of which Leadless Pacemaker is the first listed.
NCT02030418 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02030418 about?
NCT02030418 is a clinical study titled "The LEADLESS II IDE Study for the Nanostim Leadless Pacemaker". Prospective, non-randomized, single-arm, international multicenter, clinical safety and effectiveness of a leadless pacemaker system in patients who are indicated for a VVIR pacemaker. Following completion of enrollments in the IDE, patients will continue to be enrolled in the continued access phas...
What is the current status of trial NCT02030418?
This trial is currently completed. It is a NA study. The enrollment target is 952 participants. The study started on 2014-02. Estimated completion is 2022-07-15.
What interventions are being tested in trial NCT02030418?
The interventions under investigation include: Leadless Pacemaker (DEVICE).
Who is sponsoring clinical trial NCT02030418?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02030418's enrollment target sits among peer trials
952 123rd of 2000 higher than 1,878 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04375033 · 952 participants · Phase 4
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
- NCT03784924 · 950 participants
EDRN Prostate MRI Biomarker Study
- NCT04180930 · 950 participants
An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample
- NCT04895709 · 949 participants · Phase 1
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia